Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea

By: via Benzinga
UNITY Biotechnology Inc(NASDAQ: UBX)announced resultsfrom the long-term follow-up of the Phase 2 BEHOLD study of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.